Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Kaempferol 3-o-beta-d-glucopyranoside
1. 480-10-4
2. Astragaline
3. Kaempferol 3-o-glucoside
4. Kaempferol-3-glucoside
5. Kaempferol 3-glucoside
6. Kaempferol-3-o-glucoside
7. 3-glucosylkaempferol
8. Asragalin
9. Kaempferol-3-beta-monoglucoside
10. Kaempferol-3-beta-glucopyranoside
11. 3,4',5,7-tetrahydroxyflavone-3-glucoside
12. Kaempferol 3-o-beta-d-glucopyranoside
13. 4h-1-benzopyran-4-one, 3-(beta-d-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-
14. Apm8uq3z9o
15. Kaempferol 3-o-beta-d-glucoside
16. Chembl233930
17. Chebi:30200
18. Mfcd00075932
19. 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-(((2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2h-pyran-2-yl)oxy)-4h-chromen-4-one
20. Kaempferol 3-o-.beta.-d-glucopyranoside
21. Kaempferol-3-d-glucoside
22. 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
23. 3-(beta-d-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4h-chromen-4-one
24. 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-3-yl Beta-d-glucopyranoside
25. 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one
26. Unii-apm8uq3z9o
27. Kaempferol 3-beta-d-glucopyranoside, >=97.0% (hplc)
28. Astraglin
29. Kaempferol 3-beta-d-glucopyranoside
30. Kaempferol 3-d-glucoside
31. 3-o-b-d-glucopyranoside
32. Schembl23897
33. K5
34. Mls002473092
35. Megxp0_000168
36. Acon1_001224
37. Cid_5282102
38. Kaempferol 3-b-d-glucopyranoside
39. Bdbm226182
40. Dtxsid801017739
41. Hms2227a14
42. Hy-n0015
43. Kaempferol-3-o-beta-glucopyranoside
44. Zinc4102435
45. Bdbm50241243
46. S9289
47. Zb1884
48. Kaempferol 3-o-glucopyranoside
49. Akos015896779
50. Ccg-269212
51. Cs-3720
52. Kaempferol 3-o-beta-d-glucoside (6)
53. Kaempferol 3-.beta.-d-glucoside
54. Kaempferol 3-o-.beta.-glucoside
55. Kaempferol-3-o-.beta.-d-glucopyranoside
56. Ncgc00163580-01
57. Ncgc00163580-02
58. Ac-35088
59. Smr001397194
60. Kaempferol 3-o-.beta.-d-glucoside
61. Kaempferol 3-glucoside, Analytical Standard
62. 3,4'',5,7-tetrahydroxyflavone-3-glucoside
63. N1897
64. 3-((2s,3r,4s,5s,6r)-
65. Kaempferol 3-.beta.-d-glucopyranoside
66. 3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-
67. 480a104
68. A827420
69. Sr-05000002271
70. Q-100517
71. Q4811191
72. Sr-05000002271-2
73. 3-o-b-d-glucopyranosyloxy-4',5,7-trihydroxyflavone
74. Brd-k44487476-001-01-5
75. (2s,3s)-dihyrokaempferol 3-o-.beta.-d-glucoside
76. 4',5,7-trihydroxyflavone 3-.beta.-d-glucopyranoside
77. Kaempferol 3-o-glucoside (constituent Of Ginkgo) [dsc]
78. Kaempferol 3-glucoside, Primary Pharmaceutical Reference Standard
79. 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4h-chromen-3-yl .beta.-d-glucopyranoside
80. 4h-1-benzopyran-4-one, 3-(.beta.-d-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-
81. 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4h-chromen-4-one
| Molecular Weight | 448.4 g/mol |
|---|---|
| Molecular Formula | C21H20O11 |
| XLogP3 | 0.7 |
| Hydrogen Bond Donor Count | 7 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 4 |
| Exact Mass | 448.10056145 g/mol |
| Monoisotopic Mass | 448.10056145 g/mol |
| Topological Polar Surface Area | 186 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 719 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Astragalin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Astragalin, including repackagers and relabelers. The FDA regulates Astragalin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Astragalin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Astragalin supplier is an individual or a company that provides Astragalin active pharmaceutical ingredient (API) or Astragalin finished formulations upon request. The Astragalin suppliers may include Astragalin API manufacturers, exporters, distributors and traders.
Astragalin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Astragalin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Astragalin GMP manufacturer or Astragalin GMP API supplier for your needs.
A Astragalin CoA (Certificate of Analysis) is a formal document that attests to Astragalin's compliance with Astragalin specifications and serves as a tool for batch-level quality control.
Astragalin CoA mostly includes findings from lab analyses of a specific batch. For each Astragalin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Astragalin may be tested according to a variety of international standards, such as European Pharmacopoeia (Astragalin EP), Astragalin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Astragalin USP).
LOOKING FOR A SUPPLIER?
